Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518320 | SCV000612590 | uncertain significance | not specified | 2017-02-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001241845 | SCV001414894 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2025-01-30 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003487271 | SCV003828854 | uncertain significance | not provided | 2021-12-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004023496 | SCV004915022 | uncertain significance | Inborn genetic diseases | 2023-10-16 | criteria provided, single submitter | clinical testing | The c.1492C>T (p.R498C) alteration is located in exon 11 (coding exon 11) of the CACNA1S gene. This alteration results from a C to T substitution at nucleotide position 1492, causing the arginine (R) at amino acid position 498 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003487271 | SCV005326096 | uncertain significance | not provided | 2024-03-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV005004207 | SCV005630938 | uncertain significance | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5; Thyrotoxic periodic paralysis, susceptibility to, 1; Congenital myopathy 18 | 2024-06-20 | criteria provided, single submitter | clinical testing |